ClinicalTrials.gg

Program

hepalatide

Also written as “Hepalatide”, “Hepalatide 2.1mg” and “Hepalatide 4.2mg”.

Its studies are mostly in Hepatitis B, Chronic · Hepatitis D, Chronic · Hepatitis D · Diabetes Mellitus, Type 2, led by Shanghai HEP Pharmaceutical.

Furthest: phase 3, since Dec 16, 20258 company-led studies, 1 open or runningNext primary completion: Jun 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai HEP Pharmaceutical81 open or runningphase 3since Dec 16, 2025Sep 16, 2015Jun 2028phase 3 · NCT07309380

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 16, 2015First study: phase 1 study in Hepatitis B, ChronicFirst studyNCT02612506 · 48 enrolled · China
  2. Jan 15, 2017Phase 1 study in Hepatitis B, ChronicNCT03023787 · 35 enrolled · China
  3. Jun 9, 2020Phase 2 study in Hepatitis B, ChronicNCT04426968 · 96 enrolled · China
  4. Dec 3, 2020Phase 2 study in Type 2 Diabetes PatientsNCT04662164
  5. Feb 3, 2022Phase 2 study in Hepatitis B, ChronicNCT05244057 · 8 enrolled · China
  6. Feb 17, 2023Phase 2 study in Hepatitis D, ChronicNCT05827146 · 23 enrolled · China, Mongolia
  7. Jul 10, 2024Phase 2 study in Hepatitis DNCT06505928 · 90 enrolled · Mongolia
  8. Dec 16, 2025Phase 3 study in Hepatitis D, ChronicPhase 3 reachedNCT07309380 · 150 planned · China

Ahead

  1. Jun 2028Primary completion: phase 3 study in Hepatitis D, ChronicNCT07309380

TargetBeta

SLC10A1 →read by rule
“Bile acid transporter inhibitor”ChEMBL 37, by rule

Other programs on SLC10A1

ProgramCompanyFurthest phaseStudies
bulevirtideruleGilead Sciencesphase 35

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07309380Hepatitis D, Chronic · China3Not yet recruitingJun 2028150
NCT06505928Hepatitis D · Mongolia2CompletedMay 1, 202690
NCT05827146Hepatitis D, Chronic · China, Mongolia2CompletedJan 30, 202423
NCT05244057Hepatitis B, Chronic · China2CompletedJun 24, 20248
NCT04662164Type 2 Diabetes Patients2WithdrawnDec 20250
NCT04426968Hepatitis B, Chronic · China2CompletedNov 1, 202396
NCT03023787Hepatitis B, Chronic · China1CompletedDec 201635
NCT02612506Hepatitis B, Chronic · China1CompletedAug 201648

How it is read

Names in the registry

  • “Hepalatide”, 4 entries
  • “hepalatide”, 2 entries
  • “Hepalatide 2.1mg”, 2 entries
  • “Hepalatide 4.2mg”, 1 entry
  • “Hepalatide 6.3mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.